Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.42 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2798206 | 0.87 | HTR3E (0.45) | OPRM1KDM4EALDH1A1 | |
| SCHEMBL2797003 | 0.84 | KCNH2 (0.45) | KCNH2CNR1CNR2GSK3BKDM4E | |
| SCHEMBL5040389 | 0.84 | KCNH2 (0.49) | KCNH2CNR1CNR2 | |
| Hydrochloric Acid SCHEMBL2799736 | 0.83 | KCNH2 (0.44) | KCNH2CNR1CNR2KDM4EALDH1A1 | |
| SCHEMBL707943 | 0.82 | KCNH2 (0.51) | KCNH2OPRM1 | |
| SCHEMBL707117 | 0.82 | GRM2 (0.39) | KCNH2CNR1CNR2OPRM1EPHX2 | |
| SCHEMBL13234465 | 0.82 | KCNH2 (0.46) | KCNH2CNR1CNR2 | |
| SCHEMBL2799086 | 0.81 | KCNH2 (0.53) | KCNH2CNR1CNR2 | |
| SCHEMBL13235056 | 0.81 | KCNH2 (0.49) | KCNH2CNR1CNR2EPHX2 | |
| SCHEMBL707472 | 0.80 | KCNH2 (0.55) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | ROS1, NOX1, ARG1 | KCNH2 578/4885CNR1 673/4885CNR2 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.